Figure 1.
Serum AMH levels in women with sickle cell disease who had never taken HC (the HC-naive group), in those having taken HC in the past but who had discontinued the drug at least 12 months before sample collection (the past-HC group), and in those who were taking HC when the sample was collected (the HC group). The AMH level was significantly lower in the HC group than in the other 2 groups. There was no significant difference in AMH level between the HC-naive and past-HC groups. ∗P = .035 in a Kruskal-Wallis with Dunn posttest (expressed as the median [range]).

Serum AMH levels in women with sickle cell disease who had never taken HC (the HC-naive group), in those having taken HC in the past but who had discontinued the drug at least 12 months before sample collection (the past-HC group), and in those who were taking HC when the sample was collected (the HC group). The AMH level was significantly lower in the HC group than in the other 2 groups. There was no significant difference in AMH level between the HC-naive and past-HC groups. ∗P = .035 in a Kruskal-Wallis with Dunn posttest (expressed as the median [range]).

Close Modal

or Create an Account

Close Modal
Close Modal